Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633506 | 0.78 | CREBBP (0.34) | KDM4CL3MBTL1ICAM1SELE | |
| SCHEMBL13633498 | 0.77 | — | — | |
| SCHEMBL15244567 | 0.70 | KDM4C (0.37) | KDM4CL3MBTL1NPC1RAB9ADHFR | |
| SCHEMBL17888696 | 0.68 | KDM4C (0.36) | KDM4CL3MBTL1NPC1RAB9ADHFR | |
| SCHEMBL17649571 | 0.65 | KDM4C (0.33) | KDM4CL3MBTL1NPC1RAB9A | |
| SCHEMBL12168828 | 0.65 | ICAM1 (0.43) | KDM4CL3MBTL1NPC1RAB9ADHFR | |
| SCHEMBL30204914 | 0.65 | KDM4C (0.38) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL15728474 | 0.65 | KDM4C (0.38) | KDM4CL3MBTL1NPC1RAB9ADHFR | |
| SCHEMBL4724279 | 0.65 | CREBBP (0.40) | KDM4CL3MBTL1NPC1RAB9AICAM1 | |
| SCHEMBL19736987 | 0.64 | KDM4C (0.35) | KDM4CL3MBTL1NPC1RAB9AICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| EP-1737459-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191394-A1 | Antibacterial agents | MRPL21, RPN2, FBL | KDM4C 4482/4885L3MBTL1 4527/4885NPC1 575/4885 |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | DPYD, TYMP, ITPA | KDM4C 3772/4885L3MBTL1 4730/4885NPC1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.